NESSUM-ALLIANCE
21.5.2024 10:01:27 CEST | Business Wire | Press release
In a groundbreaking stride toward advancing communication standards in the digital age, the NESSUM Alliance is proud to announce the release of the IEEE 1901c standard on May 15th. This transformative standard, created from the collaborative efforts of NESSUM's esteemed members, now stands poised to redefine connectivity paradigms worldwide, under the rebranded banner of NESSUM.
With the introduction of IEEE 1901c, formerly known as 'HD-PLC,' NESSUM introduces many new and unparalleled features:
- Long-Distance Communication: Spanning several kilometers, NESSUM enables a new era of expansive reach.
- Broadband Communication: Operating in the Mbps class, this standard ensures seamless transmission of data across networks.
- IP Compatibility: Using standardized Internet Protocol (IP), NESSUM seamlessly integrates with existing infrastructures.
- Topology-Free Configuration: Facilitating flexible networking, NESSUM overcomes conventional constraints of network configurations.
- Safety and Security: Prioritizing network and user safety, NESSUM ensures robust and secure communication channels.
Besides high-speed communication on any wire, NESSUM technology also enables the transmission of weak radio signals, facilitating short-range wireless communication applications, including underwater environments. This makes it a truly versatile solution for any media.
The IEEE began the development of the any medium communication standard for IoT applications as IEEE P1901c in May 2022, including the adoption of the Wavelet OFDM method - one of the advanced feature sets of NESSUM's technological advantages compare to other (power line) solutions. After months of effort and refinement, IEEE 1901c attained formal approval in February of this year, marking a monumental leap forward in communication standards.
Mr. Jean-Philippe Faure, Chair of the IEEE 1901WG, lauded the contributions of NESSUM Alliance's expert members, affirming, "This new standard expands the application range of powerline communication to various existing lines and supports low-power radio, opening up new possibilities for high-speed short-range wireless communication."
Agreeing to this sentiment, Mr. Hiroshi Saijo, Head of Business Development & Strategy at Panasonic Holdings Corporation, articulated a shared vision of global proliferation, stating, "We aim to spread this IoT communication standard worldwide as an international standard, not only in products but also in applications."
Mr. Keishi Kajiwara, Director of the Communication Business Division at MegaChips Corporation expressed eager anticipation for market expansion and collaborative endeavors with the new standard, NESSUM's pivotal role in driving innovation.
Mr. Christopher Trabold, CTO and Business Development Leader for Asset Monitoring and Communication at General Electric Vernova, emphasized the burgeoning demand for powerline communication with the digitalization of power infrastructure, signaling a promising trajectory for IEEE 1901c.
IEEE 1901c's transformative capabilities extend to long-distance powerline communication, now covering the several hundred kHz band as NBPLC through innovative resampling. This evolutionary leap finds resonance in diverse sectors, from medium-voltage system control to smart meters, with new applications in Asia and beyond.
Mr. Markus Rindchen, Head of Technology Management at Power Plus Communications AG, pointed out the indispensable role of NESSUM in Germany's Smart Meter Gateway business, underscoring its essential role for the mass roll-out.
Mr. Tomislav Drenski, Marketing Manager at Socionext Europe GmbH is excited to promote the new NESSUM ICs. These advanced ICs offer unique features such as high speed, stable and secure long-distance communication, which surpass other power line solutions available in the market.
With a strong long-term commitment to meet evolving market demands and continuously develop innovation in the IoT landscape, the NESSUM Alliance promotes and supports Any Media communications being inter-operable worldwide. Through a multifaceted approach encompassing webinars, seminars, exhibitions, and extensive promotional activities, the alliance is confident and certain to drive future state-of-the-art solutions with increased compatibility, and lead international standardization efforts.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240521360203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
